OrbiMed’s InflaRx IFRX Stock Holding History

OrbiMed’s Portfolio IFRX Stock Details IFRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-875,297	Closed	-$4.17M	–	153
2021 Q4	$4.17M	Sell	875,297 -188,821	-18%	-$759K	0.05%	139
2021 Q3	$2.76M	Hold	1,064,118	–	–	0.03%	164
2021 Q2	$3.16M	Hold	1,064,118	–	–	0.03%	154
2021 Q1	$4.15M	Buy	1,064,118 +508,093	+91%	+$2.6M	0.04%	148
2020 Q4	$2.8M	Sell	556,025 -122,500	-18%	-$551K	0.02%	143
2020 Q3	$2.89M	Hold	678,525	–	–	0.04%	133
2020 Q2	$3.11M	Sell	678,525 -389,075	-36%	-$2.52M	0.04%	126
2020 Q1	$4.08M	Buy	+1,067,600	New	+$3.95M	0.07%	111

Other funds holding IFRX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

OrbiMed's IFRX Position: Q1 2022 in Review

OrbiMed sold out of InflaRx (IFRX) in Q1 2022, closing a stake of 875,297 shares — an estimated $4.17M sold.

OrbiMed first reported a position in IFRX in Q1 2020 and held it in 8 quarters. The position peaked at $4.17M in Q4 2021. 32 funds tracked by Wall St. Rank hold IFRX as of Q1 2022.

OrbiMed reported no remaining InflaRx position as of Q1 2022 after selling out during the quarter.
OrbiMed sold 875,297 InflaRx shares in Q1 2022, an estimated $4.17M.
OrbiMed first reported a position in InflaRx in Q1 2020 and held it in 8 quarters.
OrbiMed's InflaRx position peaked at $4.17M in Q4 2021.
32 funds tracked by Wall St. Rank held InflaRx as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.